Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor ...
Wegovy HD’s approval came on the cusp of the drug’s patent expiry in India and China, which leaves it open to some biosimilar ...
Congruence Therapeutics has completed a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results